Annexon, Inc. (ANNX)

Annexon, Inc. is trading at $4.87, down 1.42% on the session. The 50 day average sits at $5.40 and the 200 day at $5.35, which puts the stock in a uptrend. RSI is at 42.7, which reads as weak, and MACD is bearish crossover. Volume is average.

The nearest support is around $4.80 with resistance near $5.59, so that band frames the current range. Average daily movement is roughly $0.31, or about 6.3% of the share price, which is what any stop placement has to allow for. The overall health score of 38 out of 100 combines a trend score of 33, momentum of 30 and a risk score of 58.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.